As of Apr 2, 2025, the CRL stock has a PE ratio of 746.4. The calculation is based on the latest EPS of $0.2 and the stock price of $149.28 per share. An increase of 195% has been observed in the PE ratio compared to its average of 252.9 of the last four quarters.
The mean historical PE ratio of Charles River Laboratories International over the last ten years is 53.32. The current 746.4 P/E ratio is similar to the historical average. Looking back at the last ten years, CRL's PE ratio peaked in the Dec 2024 quarter at 930.8, with a price of $186.16 and an EPS of $0.2. The Apr 2023 quarter marked the lowest point at 20.68, with a price of $201.82 and an EPS of $9.76.
Maximum annual increase: 3,550.2% in 2024
Maximum annual decrease: -52.08% in 2022
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 930.8 | 3,550.2% | $186.16 | $0.2 |
2023 | 25.5 | 11.99% | $236.4 | $9.27 |
2022 | 22.77 | -52.08% | $217.9 | $9.57 |
2021 | 47.52 | 38.74% | $369.2 | $7.77 |
2020 | 34.25 | 16.54% | $251.71 | $7.35 |
2019 | 29.39 | 24.17% | $151.93 | $5.17 |
2018 | 23.67 | -43.78% | $111.72 | $4.72 |
2017 | 42.1 | 81.78% | $109.45 | $2.6 |
2016 | 23.16 | -7.17% | $76.19 | $3.29 |
2015 | 24.95 | 5.54% | $80.08 | $3.21 |
2014 | 23.64 | -4.68% | $64.29 | $2.72 |
2013 | 24.8 | 36.49% | $53.33 | $2.15 |
2012 | 18.17 | 43.64% | $36.88 | $2.03 |
2011 | 12.65 | N/A | $27.33 | $2.16 |
2010 | N/A | N/A | $35.7 | -$5.38 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 930.8 | 3,679.13% | $186.16 | $0.2 |
Sep 2024 | 24.63 | 0.29% | $198.31 | $8.05 |
Jun 2024 | 24.56 | -22.5% | $206.58 | $8.41 |
Mar 2024 | 31.69 | 24.27% | $270.95 | $8.55 |
Dec 2023 | 25.5 | 21.03% | $236.4 | $9.27 |
Sep 2023 | 21.07 | -4.79% | $195.98 | $9.3 |
Jul 2023 | 22.13 | 7.01% | $210.25 | $9.5 |
Apr 2023 | 20.68 | -9.18% | $201.82 | $9.76 |
Dec 2022 | 22.77 | 4.69% | $217.9 | $9.57 |
Sep 2022 | 21.75 | -15.73% | $187.51 | $8.62 |
Jun 2022 | 25.81 | -22.52% | $226.32 | $8.77 |
Mar 2022 | 33.31 | -29.9% | $279.1 | $8.38 |
Dec 2021 | 47.52 | -17.88% | $369.2 | $7.77 |
Sep 2021 | 57.87 | 24.88% | $458.3 | $7.92 |
Jun 2021 | 46.34 | 21.31% | $367.9 | $7.94 |
CRL's current PE ratio is higher than the 3, 5 and 10-year averages.
In comparison to its peer stock TMO, CRL's PE ratio is higher.
Stock name | PE ratio | Market cap |
---|---|---|
TMO Thermo Fisher Scientific Inc | 28.48 | $178.13B |
CRL Charles River Laboratories International Inc | 695.05 | $7.11B |
RGEN Repligen Corp | N/A | $6.91B |
SCYX Scynexis Inc | N/A | $35.4M |
CRL stock has a price to earnings ratio of 746.4 as of Apr 2, 2025.
As an average over the last 3 years, CRL stock has a PE ratio of 106.49.
As an average over the last 5 years, CRL stock has a PE ratio of 78.7.
Over the last ten years, the Dec 2024 quarter recorded the highest quarterly PE ratio at 930.8.
CRL's current price to earnings ratio is 1,300% above its 10-year historical average.
CRL's PE ratio is high because its earnings per share (EPS) is low relative to its stock price.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Apr 2, 2025), Charles River Laboratories International's share price is $149.28. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $0.2. Therefore, Charles River Laboratories International's PE ratio for today is 746.4. PE RATIO(746.4) = STOCK PRICE($149.28) / TTM EPS($0.2)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.